Editas Medicine (EDIT) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Editas Medicine insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $107K of EDIT stock on the open market.
Get emailed when insiders cluster-buy stocks like EDIT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
EDIT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $34K | 5 |
| Q2 2026 | — | 0 | $45K | 3 |
| Q1 2026 | — | 0 | $13K | 3 |
| Q4 2025 | — | 0 | $15K | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Editas Medicine, Inc. insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $107K. 14 of 14 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 4SEC | Gilmore Neil O'neillCEO | Sell Plan | 5,124243,189 held (−2%) | $3.04 | $16K | -4.6% | — |
| Sep 4SEC | Linda BurklyEvp, Chief Scientific Officer | Sell Plan | 70961,660 held (−1%) | $3.04 | $2K | -4.6% | — |
| Sep 4SEC | Amy ParisonCFO | Sell Plan | 45313,839 held (−3%) | $3.04 | $1K | -4.6% | — |
| Aug 5SEC | Amy ParisonCFO | Sell Plan | 67814,292 held (−5%) | $2.58 | $2K | +12.4% | — |
| Jul 29SEC | Linda BurklyEvp, Chief Scientific Officer | Sell Plan | 4,92862,369 held (−7%) | $2.67 | $13K | +8.6% | — |
| Jun 5SEC | Gilmore Neil O'neillCEO | Sell Plan | 15,380248,313 held (−6%) | $2.70 | $42K | +7.4% | — |
| Jun 5SEC | Linda BurklyEvp, Chief Scientific Officer | Sell Plan | 73167,297 held (−1%) | $2.70 | $2K | +7.4% | — |
| Jun 5SEC | Amy ParisonCFO | Sell Plan | 46414,970 held (−3%) | $2.70 | $1K | +7.4% | — |
| Mar 4SEC | Gilmore Neil O'neillCEO | Sell Plan | 5,394263,693 held (−2%) | $2.02 | $11K | +43.6% | — |
| Mar 4SEC | Linda BurklyEvp, Chief Scientific Officer | Sell Plan | 74968,028 held (−1%) | $2.02 | $2K | +43.6% | — |
| Mar 4SEC | Amy ParisonCFO | Sell Plan | 47415,434 held (−3%) | $2.02 | $957 | +43.6% | — |
| Dec 4SEC | Gilmore Neil O'neillCEO | Sell Plan | 5,603269,087 held (−2%) | $2.15 | $12K | +34.9% | — |
| Dec 4SEC | Linda BurklyEvp, Chief Scientific Officer | Sell Plan | 71368,777 held (−1%) | $2.15 | $2K | +34.9% | — |
| Dec 4SEC | Amy ParisonCFO | Sell Plan | 46115,908 held (−3%) | $2.15 | $991 | +34.9% | — |
Insiders at Editas Medicine, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Gilmore Neil O'neillCEO | — | $80K | Sep 4, 2026 | — |
| Linda BurklyEvp, Chief Scientific Officer | — | $20K | Sep 4, 2026 | — |
| Amy ParisonCFO | — | $6K | Sep 4, 2026 | — |
EDIT stock: common questions
Are Editas Medicine, Inc. insiders buying EDIT stock?
In the past 12 months, 0 insiders reported open-market purchases of EDIT worth $0.
Are Editas Medicine, Inc. insiders selling EDIT stock?
3 insiders reported sales worth $107K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is EDIT's 52-week range?
Over the past year EDIT has traded between $1.67 and $4.14. It last closed at $2.90 on Oct 9, 2026.